NEW YORK (GenomeWeb) – Diagnostics developer IQuity Labs announced today that it has a deal under which its autoimmune disease diagnostics will be made available through Diatherix's CLIA-certified clinical laboratory.
IQuity said it will introduce its first diagnostic — a test for multiple sclerosis — in mid-2016 with additional tests for other autoimmune diseases launching over the coming 12 months.
"The proven science and dedicated individuals behind IQuity’s tests are exactly what we look for in a strategic partner," Diatherix CEO Dennis Grimaud said in a statement. "We are confident in [the MS] test's ability to greatly improve lives through diagnosis of conditions that often go misdiagnosed for years."
Specific terms of the arrangement were not disclosed.
Diatherix, which was purchased by Eurofins Scientific in mid-2015, currently offers molecular diagnostic testing services for infectious diseases based on its proprietary target-enriched multiplexing, or TEM-PCR, technology acquired from Qiagen in 2013.